CTRI/2009/091/000568已完成2 期
A Dose tolerability and Efficacy Study of RX-0201 plus Gemcitabine in Metastatic Pancreatic Cancer - NI
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects who:
- •1. Provide written informed consent prior to the initiation of study procedures.
- •2. Are greater than 18 years of age
- •3. Have metastatic pancreatic cancer.
- •4. Have at least a measurable lesion by RECIST criteria.
- •5. Have a Karnofsky Performance Status of greater than 70.
- •6. Have at least a 6-month life expectancy as assessed by the investigator.
- •7. Pre-menopausal women must be surgically sterile or agree to use an accepted method of birth control while participating in the study and for 30 days following the last exposure of study drug. Acceptable forms of birth control are: hormonal contraceptives (oral, injectable, transdermal or implant), double-barrier contraceptives (condom or diaphragm with spermicide), and intrauterine device (IUD).
- •8. Male subjects need to either be surgically sterile or agree to use a barrier method of birth control described above during the study and for 30 days following the last exposure to study drug. The agreed method of birth control by sunject will be discussed and documented in the source document of subject during the screening phase of the study.
排除标准
- •Subjects who:
- •1. Are unwilling or unable to provide informed consent.
- •2. Are unwilling or unable to comply with the requirements of the protocol.
- •3. Have been treated with another investigational agent.
- •4. Have any of the following screening laboratory values:
- •i. Hemoglobin less than 8.0 grams/deciliter (g/dL)
- •ii. Absolute neutrophil count (ANC) less than 1500/microliter
- •iii. Platelet count less than 100,000/microL
- •iv. Serum creatinine greater than 1.5 x the institutional upper limit of normal (IULN) creatinine.
- •v. Serum bilirubin greater than 1.5 X IULN
- •vi. Aspartate transaminase (AST) (serum glutamic oxaloacetic transaminase, SGOT) greater than 2 x IULN (greater than 5 x IULN in presence of known liver metastasis)
- •vii. Alanine transaminase (ALT) (serum glutamate pyruvate transaminase, SGPT) greater than 2 x IULN (greater than 5 x IULN in presence of known liver metastasis)
- •viii. Have a prothrombin time greater than 1.25 x IULN on screening laboratory assessments.
- •ix. Lack Lewis antigens
- •x. HCV, and HBsAg positive Subjects
- •xi. CA 19-9 less than 75 U/ml
- •5. Have received either warfarin or heparin treatment within 21 days before Day 1 (the first day of dosing; except for line dose of prophylactic warfarin or heparin).
- •6. Have a history of brain cancer (primary or metastatic).
- •7. Have a history of an active hematologic malignancy within the past 2 years.
- •8. Have an underlying diagnosis or disease state associated with an increased risk of bleeding (i.e., coagulopathies, HIV).
- •9. Have a serious infection requiring intravenous antibiotic therapy during screening.
- •10. Females who are pregnant, lactating, or have a positive serum pregnancy test during the screening period.
研究者
相似试验
未知
2 期
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary HypercholesterolemiaHypercholesterolemiaJPRN-jRCT2080222170Eli Lilly Japan K.K.
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolEUCTR2013-000622-55-DKEli Lilly and Company528
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolEUCTR2013-000622-55-NLEli Lilly and Company528
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolPrimary hypercholesterolaemiaMedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000622-55-CZEli Lilly and Company528
已完成
2 期
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemiahypercholesterolaemiahigh blood cholesterol levelsNL-OMON38601Eli Lilly80